Summit Therapeutics

Promising C. difficile drug ridinilazole has failed in Phase 3, CARB-X grantee Summit Therapeutics announced Monday.

The Massachusetts-based company said the study showed that the investigational drug resulted in a higher observed Sustained Clinical Response rate than current standard-of-care vancomycin “but did not meet the study’s primary endpoint for superiority.”

The company did see a “meaningful reduction in recurrence,” however, which Summit Therapeutics linked to the…

A therapy for the prevention of recurrent C. difficile infection (CDI) in high-risk patients has met the primary endpoint in a Phase 2 trial, Vedanta Biosciences announced Tuesday. The Massachusetts-based company’s VE303, an orally administered live biotherapeutic, yielded a 31.7% absolute risk reduction in rate of recurrence versus placebo, according to a press release.

Based on the Phase 2 data, the U.S. Biomedical Advanced Research and Development Authority (BARDA) exercised an…

Boston University’s CARB-X consortium announced two new investments this week.

On Tuesday, the nonprofit said it will give Massachusetts-based Summit Therapeutics up to $4.1 million (plus up to $3.7 million in milestones) to develop its first-in-class SMT-738 antibiotic candidate for treating multidrug-resistant infections—specifically carbapenem-resistant Enterobacteriaceae (CRE) infections caused by pathogens including E. coli and K. pneumoniae. The funds will help advance the…

Merck announced this week that the U.S. FDA has approved Dificid (fidaxomicin)—its macrolide antibiotic oral suspension and tablet for the treatment of C. difficile-associated diarrhea in children 6 months and older. The agency granted priority review for the drugs in October 2019.

In other antibiotic news, Oxford-based Summit Therapeutics announced last week that the U.S. Biomedical Advanced Research and Development Authority has awarded it an additional $8.8 million to test its C.…

CARB-X announced yesterday that it is giving Summit Therapeutics up to $4.5 million to develop a new class of antibiotic compounds against gonorrhea.

The Oxford-based company has identified a series of novel class/novel target compounds that have shown high potency against a range of Neisseria gonorrhoeae strains, including multi-drug resistant ones, CARB-X said in a press release.